Full detail content for this treatment is being translated. For a localized consultation in English, please contact our coordinators — we respond within 24 hours.
NK-Cell Therapy and Checkpoint-Drug Consultation
NK Cell Therapy + Checkpoint Inhibitor Consultation
NK-cell therapy and checkpoint inhibitors such as Opdivo or Yervoy require case-by-case review based on cancer type, prior treatment, biomarkers, overall condition, and adverse-event risk. Low-dose or combination regimens should not be described as guaranteed or safer.
The Double Synergy of NK Cells and Immune Checkpoints
NK Cells: Natural Killers
Natural killer (NK) cells are the first line of defense in the immune system, recognizing and attacking cancer cells without the need for antigen presentation. An 11-year follow-up of 3,625 residents aged 40–80 showed that people with lower NK-cell activity had a markedly higher cancer incidence.
Immune Checkpoint Inhibitors
PD-L1 on cancer cells binds PD-1 on T cells and sends a "stop attacking" signal. Opdivo blocks PD-1 and Yervoy blocks CTLA-4, so that once immune suppression is lifted, T cells are free to attack cancer cells. Prof. Tasuku Honjo of Japan was awarded the 2018 Nobel Prize in Physiology or Medicine for discovering this mechanism.
Four Key Technical Advantages
Low-Dose Medication Requires Strict Review
Checkpoint inhibitors such as Opdivo and Yervoy can cause serious immune-related adverse events. If a clinic discusses low-dose or combination use, confirm whether it is self-pay or off-label, the eligibility criteria, monitoring plan, and emergency response; do not promise efficacy or safety.
Dual Release of PD-1 and CTLA-4
Opdivo blocks the PD-1/PD-L1 interaction between T cells and cancer cells, while Yervoy targets CTLA-4 to lift another layer of immune suppression. Together they awaken a multi-axis immune attack on the tumor.
BAK Immune-Cell Therapy Requires Case Review
BAK therapy is a self-pay treatment option. Clinic materials may be used as consultation references, but suitability, current availability, and whether it can run alongside standard care should be reviewed case by case by the treating physician.
iNKT-Cell Therapy: the Fourth Lymphocyte Lineage
Maki Clinic offers iNKT immunotherapy. Once activated, this fourth lymphocyte lineage releases IFN-γ to boost both NK and killer-T-cell attack, eliminates several cancer-cell subtypes simultaneously, and establishes long-lasting immune memory.
Treatment Process
Blood Work and Evaluation
Detailed history taking, comprehensive blood tests and assessment of treatment eligibility and individualized dosing.
Blood Draw and Cell Separation
About 40–50 ml of blood is drawn; lymphocytes are isolated and NK cells are activated and expanded in a sterile CPC facility over roughly 2–3 weeks.
Medication Eligibility Review
If checkpoint inhibitors such as Opdivo or Yervoy are discussed, physician review must confirm eligibility, contraindications, immune-related adverse-event risk, fees, and follow-up.
NK-Cell Infusion
Cultivated NK cells are returned by intravenous infusion. Any combination with other cancer treatment requires physician review of timing, purpose, and risk.
Six Partner Medical Institutions in Japan
Summarizes public consultation information on NK, BAK, iNKT, and checkpoint-related care at Japanese partner clinics; availability, combinations, and risk require case-by-case confirmation.
Hiroi Clinic
Nishinomiya, Hyogo Prefecture
Checkpoint-drug and NK-cell combination consultation
Dr. Nobuyuki Hiroi, Director
Nagoya Maki Clinic
Nagoya City, Aichi Prefecture
Pioneered low-dose Opdivo efficacy in 2015; iNKT-cell therapy
Dr. Saiji Saito, Director
Akasaka AA Clinic
Minato Ward, Tokyo
BAK immune-cell therapy, IV nutrition, and self-pay care consultation
Dr. Yoshiomi Mori, Director
Ikebukuro Clinic
Toshima Ward, Tokyo
NK + αβT cell + dendritic-cell combination therapy
Chairman Dr. Yohei Ko
Ginza PHOENIX Clinic
Chiyoda Ward, Tokyo (Akihabara)
High-activity NK cells + stem-cell therapy + gene therapy
Four common concerns — and honest answers
Specific answers depend on your medical record and your attending physician. We ensure language is not a barrier to your understanding.
Q1Will it hurt?
Pain depends on the person and the procedure. Japanese hospitals follow a complete pain-management workflow: pre-procedure assessment, intra-procedural anaesthesia, and post-procedural pain control. You can ask your attending physician about expected pain at the pre-procedure briefing — our interpreter will translate question and answer accurately.
Q2How serious are the side effects?
Side effects differ by therapy. Before you sign consent, Japanese hospitals will walk you through the possible side effects, their probability, and how they are managed. If anything is unclear, we will ask the physician to re-explain until you fully understand before signing.
Q3How long is the hospital stay?
It depends on the therapy. Day treatments require no admission; some therapies need 1–3 days of observation; surgery or particle therapy may need 1–3 weeks. Your physician will note the duration in the treatment plan, and we translate the plan for you and your family.
Q4How soon after treatment can I fly home?
Day treatments and outpatient therapies usually allow same-day or next-day flights. For therapies with hospitalisation, you typically observe for 2–3 days post-discharge, and your physician issues a fitness-to-fly note. We help you book a flexible return ticket.
This section is general guidance. Specific expectations, suitability, and timing must be determined by your attending physician in Japan based on your complete medical record.
Medical information disclaimer
The information on this page is for educational reference only and does not constitute medical advice. The suitability, side effects, and expected outcomes of any therapy must be determined by your attending physician in Japan based on your complete medical record. Medical Supporter does not replace any professional medical judgement.
Ready to Explore NK Cells and Immune-Checkpoint Options?
Medical Supporter connects you with six leading Japanese immune-cell therapy centers; our specialist coordinators help you assess the most suitable low-dose regimen.